Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
JOHNSON & JOHNSON completed an acquisition involving ABIOMED for approximately $17.1 billion (closed 2022-12-22).
- Action
- acquisition
- Counterparty
- ABIOMED
- Consideration
- approximately $17.1 billion
- Closing
- 2022-12-22
Exact text from the filing
in each case, multiplied by the number of Shares underlying such ABIOMED RSU. The aggregate amount paid by Purchaser in the Offer and the Merger for the Shares was approximately $17.1 billion, excluding related fees and expenses. Johnson & Johnson and Purchaser funded the acquisition of the Shares in the Offer and the Merger through a combination of Johnson &
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
JOHNSON & JOHNSON entered into Contingent Value Rights Agreement with American Stock Transfer & Trust Company, LLC valued at Each CVR represents the non-tradeable contractual right to receive contingent cash payments of up to (effective 2022-12-22).
- Action
- entry
- Counterparty
- American Stock Transfer & Trust Company, LLC
- Value
- Each CVR represents the non-tradeable contractual right to receive contingent cash payments of up to
- Effective
- 2022-12-22
Exact text from the filing
on December 22, 2022, Johnson & Johnson and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, entered into a Contingent Value Rights Agreement (the “ CVR Agreement ”) governing the terms of the CVRs (as defined below) issued pursuant to the Offer and the Merger (as defined below).
View on SEC.gov